U.S. Markets close in 4 hrs 6 mins

IPO Outlook For The Week: Cannabis, Cancer Therapy, Sushi And Holographic AR

Elizabeth Balboa

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. The IPO dates below are expected but not confirmed.

Dynatrace Holdings LLC (DT) will issue nearly 35.6 million shares between $11 and $13 Thursday on the New York Stock Exchange. The offering represents 12.3% of outstanding shares and is expected to raise about $532 million. Founded in 2014, Dynatrace provides cloud monitoring to optimize and improve the customer support of digital applications.

Kura Sushi USA, Inc. (KRUS) will issue 2.9 million shares between $14 and $16 Thursday on the Nasdaq. The offering represents 42% of outstanding shares and is expected to raise about $53.4 million. Since its inception in 1977, the sushi chain has grown to operate more than 400 dining sites across Japan, Taiwan and five U.S. states.

Rapt Therapeutics, Inc. (RAPT) will issue 5 million shares between $14 and $16 Thursday on the Nasdaq. The offering represents 22% of outstanding shares and is expected to raise $92 million. Headquartered in San Francisco, the biotech company develops oral therapies for oncological and inflammatory diseases.

Sundial Growers Inc. (SNDL) will issue 10 million shares between $12 and $14 Thursday on the Nasdaq. The offering represents 12.1% of outstanding shares and is expected to raise $161 million. The Alberta cannabis producer markets six product series for Canadian consumers.

Wimi Hologram Cloud Inc. (WIMI) will issue 4 million shares between $7.50 and $9.50 Friday on the Nasdaq. The offering represents 100% of outstanding shares and is expected to raise $43.7 million. Based in Beijing, Wimi supports advertisers and entertainment companies with holographic software, content production and content distribution.

Related Links:

What Is Reg A+?

What Is A Lock-Up Expiration Date And Why Is It Important?

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.